Also known as: Paxlovid
Ensitrelvir cut symptomatic COVID-19 after household exposure from 9% to 3% in a trial; Japan approved it for post-exposure use. A redesigned hepatitis C drug, ML2006a4, shows activity against resistant variants.
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
